Investment

Company alerts ❯

• June 2, 2023
  Stealth BioTherapeutics

  Stealth BioTherapeutics (NAS: MITO)

  LT 2419

  419 of 521

  Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Our team works with patients and advocacy organizations to better understand their journey with mitochondrial disease and raise awareness of the unmet need our programs seek to address.

  Longevity pillar

  • Treatment
  • Prevention

  Longevity domain:

  • Longevity drugs
  • Neuropharma
  • Discovery platforms

  Longevity target: Aging Driver, Aging Disease

  and Pharmanovia partner for commercialisation of elamipretide. Read more
• June 2, 2023
  Adiso Therapeutics

  ADISO therapeutics

  LT 2012

  12 of 521

  ADISO therapeutics creates novel therapies for inflammatory diseases. Current treatment paradigms are far too often either inadequate to halt disease progression or burden the patient with significant safety concerns. To tackle these challenges, ADISO therapeutics are advancing an innovative pipeline of small molecules and single strain live biotherapeutic products (SS-LBP) both with novel mechanisms of action.

  Longevity pillar

  • Prevention
  • Treatment

  Longevity domain:

  • Longevity immunity

  Longevity target: Aging Driver

  announces the completion of a phase 1b for the treatment of moderately-to-severely active ulcerative colitis. Read more
• June 1, 2023
  Seal Rock Therapeutics

  Seal Rock therapeutics

  LT 2394

  394 of 521

  Seal Rock therapeutics discovery and development efforts are focused on small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein that when activated under a variety of stressful disease conditions can drive severe pathological outcomes including fibrosis and inflammation. The company’s lead clinical indication is non-alcoholic steatohepatitis (NASH), while its expanding R&D pipeline offers additional compelling high unmet need disease opportunities, including alcoholic hepatitis (AH), chronic kidney disease, heart failure and Parkinson’s disease

  Longevity pillar

  • Treatment
  • Prevention

  Longevity domain:

  • Longevity immunity
  • Discovery platforms

  Longevity target: Aging Disease, Aging Driver

  announces out-licensing agreement with GENFIT. Read more
• May 31, 2023
  Humacyte

  Humacyte Inc.

  LT 2205

  205 of 521

  Humacyte is pioneering the development and manufacture of off-the-shelf, universally implantable bioengineered human tissues. The Humacyte Human Acellular Vessel (HAV) is a regenerative vascular conduit currently in various stages of clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. 

  Longevity pillar

  • Renewal
  • Treatment

  Longevity domain:

  • Regeneration

  Longevity target: Aging Disease

  grows human blood vessels and sends them to wounded Ukraine soldiers. Read more
• May 30, 2023
  Athersys

  Athersys (NAS: ATHX)

  LT 2048

  48 of 521

  Athersys are developing MultiStem®, a patented, adult-derived "off-the-shelf" stem cell therapy platform, for disease indications in areas of neurological, inflammatory & immune, and cardiovascular disease areas, as well as other critical care indications where there is substantial unmet medical need due to the limitations in standard of care.

  Longevity pillar

  • Treatment
  • Renewal

  Longevity domain:

  • Regeneration

  Longevity target: Aging Driver, Aging Disease

  files to sell 5.685mn shares of common stock for holders. Read more
• May 30, 2023
  Heartseed

  Heartseed

  LT 2202

  202 of 521

  Heartseed produce a large amount of ventricular type cardiomyocytes from iPS cells. Heartseeds original purification method (patented in major countries), which eliminates undifferentiated cells and non-cardiomyocytes, minimizes the risk of teratoma formation and arrhythmia.

  Longevity pillar

  • Renewal
  • Treatment

  Longevity domain:

  • Regeneration

  Longevity target: Aging Disease

  bags $14mn Series D. Read more